-
Don’t wait until it’s too late to consider drug-drug interactions: Enzyme inhibition and induction evaluation
Patients are often treated with multiple simultaneous medications, which generates a […]
-
Quantitative bioanalysis: your project, our team of experts!
High-quality bioanalytical capabilities are one of the cornerstones in ADME/DMPK research. […]
-
Admescope increases capacity and capability in high-quality service production through new investments
As summer draws to a close, the Admescope team has been […]
-
Remember to characterize the physicochemical parameters of your compounds early on
Physicochemical parameters give valuable information about the drug-likeness of the molecules. Solubility […]
-
Symeres acquires Organix Inc., adding lipids expertise and a strategic foothold in the US
SYMERES PRESS RELEASE Nijmegen, The Netherlands – April 26, 2022: Symeres, […]
-
Is your drug development program lacking in vitro drug-drug interaction data?
We can support you with the safety evaluation required for investigational […]
-
In vivo metabolite identification and safety evaluation of human metabolites
To support understanding whether the drug metabolites can be considered safe, […]
-
New article on physiologically based pharmacokinetic modeling
Admescope’s top expert on physiologically based pharmacokinetic (PBPK) modeling, Dr Aki Heikkinen, […]
-
Admescope team welcomes a new CEO!
We are excited to announce Admescope team growing with an appointment of Dr […]
-
Do you need support with your Biologics project?
Admescope has been providing research services for biologics over few years now. We […]
-
New Admescope e-book is out!
Since Admescope’s previously published six e-books have been taken very well […]
-
Press Release: Symeres, a leading European CRO and CDMO, joins forces with Keensight Capital
We are pleased to let you know that Keensight Capital, one […]
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
